Study of eye safety during treatment with MIRV for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a targeted drug called mirvetuximab soravtansine (MIRV) for recurrent ovarian cancer that has high levels of a protein called FRα. The study focuses on monitoring and preventing eye-related side effects, which are common with this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a specific protein (FRα).
- You have been tested for this protein using a special test (VENTANA FOLR1 test).
- If you have a BRCA gene mutation, you must have already received a PARP inhibitor treatment.
- You must have finished your last cancer treatment at least 4 weeks (or 5 half-lives, whichever is shorter) before starting the study drug.
- You have recovered from any side effects of prior treatments (except hair loss).
- You do not have serious eye problems like corneal disease, uncontrolled glaucoma, or vision worse than 20/70 in either eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a PARP inhibitor (olaparib) for people whose ovarian cancer came back at least 6 months after finishing platinum-based chemo. The goal is to see if this approach is safe and works better than chemo alone.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This Phase 2 trial tests a combination of two medicines (mirvetuximab soravtansine and olaparib) as ongoing “maintenance” treatment after your best response to prior platinum chemotherapy. It may help keep cancer from growing longer in certain women whose tumors strongly match a specific marker (FRalpha).
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
This study tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian cancer that has a specific protein (FRα). It's real-world research to see how well the drug works and how it affects people's daily lives.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.